AI brief of an SEC Form 8-K · CONMED (CNMD)

CONMED enters $750 million credit agreement extending maturity to June 10, 2030

Neutral Impact 4 of 5 financing Written later

CONMED Corporation and subsidiary Linvatec Nederland B.V. entered into an Eighth Amended and Restated Credit Agreement on June 10, 2025, with JPMorgan Chase Bank, N.A. as administrative agent. The agreement replaces the 2021 credit agreement, extends maturities to June 10, 2030, and makes several covenant changes, including a new minimum interest coverage ratio of 2.75 to 1.00.

Key points

  • Facilities total $750 million: a $550.0 million U.S. dollar revolver, a $100.0 million multicurrency revolver and a $100.0 million term loan.
  • On the closing date, CONMED drew $16.0 million on the revolvers to repay existing revolving borrowings in full.
  • Maturities extended to June 10, 2030; the fixed charge coverage covenant was removed and a minimum interest coverage ratio of not less than 2.75 to 1.00 was added.
  • Borrowings are secured by assets of CONMED and certain subsidiaries, and the filing notes a minimum liquidity covenant of at least $75 million plus early maturing debt tied to convertible notes.

The filing

CompanyCONMED (CNMD)
Form8-K, current report
Filed with the SECJun 16, 2025, 4:31 PM ET
Accession number0001174947-25-000941

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 16, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.